Legend Biotech (LEGN) Equity Average (2020 - 2025)

Legend Biotech (LEGN) has 6 years of Equity Average data on file, last reported at $1.0 billion in Q1 2025.

• In Q1 2025, Equity Average fell 14.79% year-over-year to $1.0 billion; the TTM figure through Mar 2025 stood at $1.0 billion (down 14.79% YoY), while the FY2024 annual figure was $1.1 billion, up 14.84% from the prior year.
• Equity Average eased to $1.0 billion in Q1 2025, from $1.1 billion in the prior quarter.
• Across five years, Equity Average topped out at $1.4 billion in Q3 2023 and bottomed at $273185.0 in Q2 2021.
• A 5-year average of $833.8 million and a median of $1.0 billion in 2023 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2021 — Equity Average jumped 30638.63% — and 2024, when it fell 17.17%.
• Year by year, Equity Average stood at $495.9 million in 2021, then soared by 51.95% to $753.6 million in 2022, then soared by 71.92% to $1.3 billion in 2023, then decreased by 16.76% to $1.1 billion in 2024, then slipped by 4.56% to $1.0 billion in 2025.
• The last three Equity Average figures came in at $1.0 billion (Q1 2025), $1.1 billion (Q4 2024), and $1.1 billion (Q3 2024), per Business Quant data.

Peer Comparison